Reports Q1 revenue $39.08M, consensus $36M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CRMD Earnings this Week: How Will it Perform?
- Promising Growth and Adoption of CorMedix’s DefenCath: A Buy Recommendation
- Biotech Alert: Searches spiking for these stocks today
- Positive Outlook and Strong Market Demand Justify Buy Rating for CorMedix
- Cormedix’s Promising Growth Trajectory and Strategic Initiatives Support Buy Rating